Teva Respiratory has launched its AirDuo Digihaler fluticasone propionate / salmeterol and ArmonAir Digihaler fluticasone propionate DPIs in the US, the company said. The company announced the launch of its ProAir Digihaler albuterol sulfate DPI in July 2020. AirDuo Digihaler was approved by the FDA for the treatment of asthma in July 2019, and the agency approved ArmonAir Digihaler for the treatment of asthma in February 2020.
According to Teva, the list price for the 55/14 mcg and 113/14 mcg doses of AirDuo Digihaler is $399; for the 232/14 mcg dose, the list price is $449. The lower doses of ArmonAir Digihaler will list for $239, with the 232 mcg dose listed at $299. The Digihaler devices include integrated sensors to measure and store peak inspiratory flow and other inhaler use data, which can be uploaded to an app via Bluetooth.
Teva Pharmaceuticals Executive VP, North America Commercial, Brendan O’Grady commented, “Being able to now offer AirDuo Digihaler and ArmonAir Digihaler to patients is an exciting step forward for Teva, and one that we are extremely proud of. With the launch of these two maintenance products, we’re now able to offer the full Digihaler portfolio to patients, potentially allowing them to gain an even deeper understanding of their overall asthma treatment regimen due in part to the data collection capabilities of the Digihaler portfolio of products.”
Read the Teva Pharmaceutical press release.
